10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

STK11 (LKB1) Antibody (N-term V34) Blocking peptide

Synthetic peptide
Catalog # BP7239d

Specification

STK11 (LKB1) Antibody (N-term V34) Blocking peptide - Product Information

Primary Accession Q15831

STK11 (LKB1) Antibody (N-term V34) Blocking peptide - Additional Information

Gene ID 6794

Other Names
Serine/threonine-protein kinase STK11, Liver kinase B1, LKB1, hLKB1, Renal carcinoma antigen NY-REN-19, STK11, LKB1, PJS

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP7239d was selected from the N-term region of human STK11. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

STK11 (LKB1) Antibody (N-term V34) Blocking peptide - Protein Information

Name STK11 (HGNC:11389)

Synonyms LKB1, PJS

Function
Tumor suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage response. Acts by phosphorylating the T-loop of AMPK family proteins, thus promoting their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not MELK. Also phosphorylates non-AMPK family proteins such as STRADA, PTEN and possibly p53/TP53. Acts as a key upstream regulator of AMPK by mediating phosphorylation and activation of AMPK catalytic subunits PRKAA1 and PRKAA2 and thereby regulates processes including: inhibition of signaling pathways that promote cell growth and proliferation when energy levels are

low, glucose homeostasis in liver, activation of autophagy when cells undergo nutrient deprivation, and B-cell differentiation in the germinal center in response to DNA damage. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton. Required for cortical neuron polarization by mediating phosphorylation and activation of BRSK1 and BRSK2, leading to axon initiation and specification. Involved in DNA damage response: interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to participate in transcription activation. Able to phosphorylate p53/TP53; the relevance of such result in vivo is however unclear and phosphorylation may be indirect and mediated by downstream STK11/LKB1 kinase NUAK1. Also acts as a mediator of p53/TP53-dependent apoptosis via interaction with p53/TP53: translocates to the mitochondrion during apoptosis and regulates p53/TP53-dependent apoptosis pathways. Regulates UV radiation-induced DNA damage response mediated by CDKN1A. In association with NUAK1, phosphorylates CDKN1A in response to UV radiation and contributes to its degradation which is necessary for optimal DNA repair (PubMed:25329316).

Cellular Location
Nucleus. Cytoplasm. Membrane. Mitochondrion. Note=A small fraction localizes at membranes (By similarity). Relocates to the cytoplasm when bound to STRAD (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta) Translocates to the mitochondrion during apoptosis. PTEN promotes cytoplasmic localization.

Tissue Location
Ubiquitously expressed. Strongest expression in testis and fetal liver

STK11 (LKB1) Antibody (N-term V34) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

STK11 (LKB1) Antibody (N-term V34) Blocking peptide - Images

STK11 (LKB1) Antibody (N-term V34) Blocking peptide - Background

STK11, is a member of the serine/threonine kinase family, regulates cell polarity and functions as a tumor suppressor. Mutations in STK11 have been associated with Peutz-Jeghers syndrome, an autosomal dominant disorder characterized by the growth of polyps in the gastrointestinal tract, pigmented macules on the skin and mouth, and other neoplasms.

STK11 (LKB1) Antibody (N-term V34) Blocking peptide - References

Mart, et al., J. Biotechnol. 115(1):23-34 (2005).Shaw, R.J., et al., Proc. Natl. Acad. Sci. U.S.A. 101(10):3329-3335 (2004).Suzuki, A., et al., Biochem. Biophys. Res. Commun. 324(3):986-992 (2004).Hearle, N., et al., Genes Chromosomes Cancer 41(2):163-169 (2004).Corradetti, M.N., et al., Genes Dev. 18(13):1533-1538 (2004).